CAR-T cells
chimeric antigen receptor T (CAR-T) cell therapy is an adoptive immunotherapy in which a patient's own T lymphocytes are genetically engineered to express synthetic surface receptors — chimeric antigen receptors (CARs) — that redirect cytotoxic killing toward tumor cells expressing a specified antigen.
chimeric antigen receptor T (CAR-T) cell therapy is an adoptive immunotherapy in which a patient's own T lymphocytes are genetically engineered to express synthetic surface receptors — chimeric antigen receptors (CARs) — that redirect cytotoxic killing toward tumor cells expressing a specified antigen. A CAR construct typically fuses an extracellular antigen-binding domain (most commonly a single-chain variable fragment, or scFv, derived from a monoclonal antibody) to intracellular signaling domains such as CD3ζ and co-stimulatory modules (e.g., 4-1BB or CD28), enabling T-cell activation independent of MHC presentation. Following ex vivo expansion and reinfusion, CAR-T cells can traffic to disease sites, recognize target antigen, and mount a sustained cytotoxic response.
CAR-T cell therapies have demonstrated landmark clinical efficacy in B-cell malignancies — including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma — establishing the platform as a paradigm shift in oncology. Research frontiers now address key limitations including manufacturing complexity and delay, T-cell exhaustion, limited persistence, immunosuppression within the tumor microenvironment, and poor efficacy against solid tumors. Expanding the reach of CAR-T platforms beyond hematologic cancers, and into infectious diseases and fibrotic conditions, is an active area of translational investigation.
Where the papers sit
26 papers from the last 6 months study CAR-T cells directly · updated from PubMed 10 Oct 2026
Study type 2 clinical trials · 3 observational · 3 human data · 14 preclinical · 4 unclassified
Themes 3 themes · 1 paradigm shift
-
CAR-T Therapy in Solid Tumors
Solid-tumor CAR-T therapy is moving toward combined control of antigen heterogeneity, immune suppression and poor tissue access. Regnase-1 targeting, CD28-ICOS costimulation, TNC armoring and local hydrogel delivery aim to improve persistence and cytotoxicity. Radiopharmaceuticals, oncolytic adenovirus and bispecific engagers provide complementary tumor sensitization or recruitment. Spatial screening, ecosystem simulation and in vivo programming are emerging alongside these therapeutic designs.
14 papers · 53.8%
-
CD19 CAR-T Therapy
CD19 CAR-T therapy is moving from salvage treatment toward consolidation, long-term disease control and use beyond B-cell malignancies. Outcomes recur around event-free survival, cytokine release syndrome and the contribution of endogenous immune cells after infusion. BTK inhibitor pretreatment may improve tumor sensitivity, while donor-derived products and locally produced cells broaden delivery models. Studies in myasthenia gravis and glioblastoma test whether CAR-based immune remodeling can extend beyond conventional lymphoma and leukemia.
7 papers · 26.9%
-
Multiple Myeloma Care
Multiple myeloma care is increasingly shaped by commercial CAR-T access, survivorship needs and population-level treatment outcomes. Real-world studies track treatment patterns, mortality and health-care costs alongside the promise of in vivo CAR-T approaches. Interdisciplinary follow-up after cellular therapy, including the SPIZ trial, targets morbidity and continuity of care. Diagnostic and analytical advances support more precise selection and monitoring, but their clinical impact remains to be established.
5 papers · 19.2%
CAR-T cells can treat pathogenic nonmalignant disease, not only malignancy
The refractory myasthenia gravis case series and the PAR1-targeted liver-fibrosis mouse model independently use CAR-T cells against nonmalignant disease targets: anti-CD19 CAR-T cells produced sustained, treatment-free remission in three patients with severe myasthenia gravis despite persistent autoantibodies, while PAR1-CAR-T cells eliminated activated hepatic stellate cells and attenuated fibrosis in mice. Together, these findings replace the cancer-centered assumption underlying the other studies with a broader therapeutic role for CAR-T cells in removing pathogenic immune or stromal cells in nonmalignant disease 42628528Aug 42385355Jul.
Papers
The 26 papers from the last 6 months that study CAR-T cells directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CAR-T Therapy in Solid Tumors (14)
- Extracellular matrix-targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors. Science advances · 9 Oct 2026 PMID 42853935
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Science advances · 2 Oct 2026 PMID 42826199
- CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers. Journal for immunotherapy of cancer · 18 Sept 2026 PMID 42759981
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
- A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors. Science advances · 28 Aug 2026 PMID 42664321
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell reports. Medicine · 25 Aug 2026 PMID 42641597
- Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity. Journal of virology · 14 Aug 2026 PMID 42599109
- CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
- Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470101
- Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jul 2026 PMID 42385355
- MISSTE: a multiscale integrative spatial simulator for understanding the mechanisms underlying tissue ecosystems. Computers in biology and medicine · 28 Jun 2026 PMID 42365718
- A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
- Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
- CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. International immunopharmacology · 6 Jun 2026 PMID 42250288
CD19 CAR-T Therapy (7)
- Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients. Cancer chemotherapy and pharmacology · 17 Sept 2026 PMID 42752932
- Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. Cell reports. Medicine · 21 Aug 2026 PMID 42628528
- Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. Journal of cellular and molecular medicine · 30 Jul 2026 PMID 42528053
- Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. British journal of haematology · 6 Jul 2026 PMID 42410301
- CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood advances · 24 Jun 2026 PMID 42341322
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell · 15 Jun 2026 PMID 42296961
- CAR-neutrophils produced in vivo to treat glioma. Nature biomedical engineering · 24 Apr 2026 PMID 42032037
Multiple Myeloma Care (5)
- The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model. Annals of hematology · 26 Sept 2026 PMID 42799871
- Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. Current medical research and opinion · 26 Aug 2026 PMID 42642985
- In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I. Cancer discovery · 9 Jun 2026 PMID 42261652
- Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023. Oncotarget · 28 Apr 2026 PMID 42047296
- Recent Advances in Analytical Techniques for Cancer Diagnostics and Therapeutics: Combining State-of-the-Art Technologies for Precision Oncology. Critical reviews in analytical chemistry · 15 Apr 2026 PMID 41983744
By study type
Clinical trials (2)
- The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model. Annals of hematology · 26 Sept 2026 PMID 42799871
- CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood advances · 24 Jun 2026 PMID 42341322
Observational studies and case reports (3)
- Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients. Cancer chemotherapy and pharmacology · 17 Sept 2026 PMID 42752932
- Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. Cell reports. Medicine · 21 Aug 2026 PMID 42628528
- Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023. Oncotarget · 28 Apr 2026 PMID 42047296
Human data, design not indexed (3)
- Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity. Journal of virology · 14 Aug 2026 PMID 42599109
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell · 15 Jun 2026 PMID 42296961
- In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I. Cancer discovery · 9 Jun 2026 PMID 42261652
Preclinical: animal, cell and lab studies (14)
- Extracellular matrix-targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors. Science advances · 9 Oct 2026 PMID 42853935
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Science advances · 2 Oct 2026 PMID 42826199
- CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers. Journal for immunotherapy of cancer · 18 Sept 2026 PMID 42759981
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
- A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors. Science advances · 28 Aug 2026 PMID 42664321
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell reports. Medicine · 25 Aug 2026 PMID 42641597
- Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. Journal of cellular and molecular medicine · 30 Jul 2026 PMID 42528053
- CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
- Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470101
- Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jul 2026 PMID 42385355
- MISSTE: a multiscale integrative spatial simulator for understanding the mechanisms underlying tissue ecosystems. Computers in biology and medicine · 28 Jun 2026 PMID 42365718
- A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
- Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
- CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. International immunopharmacology · 6 Jun 2026 PMID 42250288
Unclassified: not yet indexed with MeSH (4)
- Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. Current medical research and opinion · 26 Aug 2026 PMID 42642985
- Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. British journal of haematology · 6 Jul 2026 PMID 42410301
- CAR-neutrophils produced in vivo to treat glioma. Nature biomedical engineering · 24 Apr 2026 PMID 42032037
- Recent Advances in Analytical Techniques for Cancer Diagnostics and Therapeutics: Combining State-of-the-Art Technologies for Precision Oncology. Critical reviews in analytical chemistry · 15 Apr 2026 PMID 41983744
Written from 26 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-20 by GPT. Drafted by language models from published abstracts; not medical advice.